Business Context and Reporting Period
Mangoceuticals, Inc. (MGRX) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. The Company operates a telemedicine platform focused on men's wellness, offering compounded products for erectile dysfunction, hair loss, hormone balance, and weight management, alongside an FDA-approved oral testosterone therapy. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
A significant corporate event occurred during the quarter: a 1-for-15 reverse stock split became effective on October 16, 2024. All share and per-share data in this filing have been retroactively adjusted to reflect this split.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenues | $133,368 | $245,160 | $510,626 | $487,119 |
| Gross Profit | $82,671 | $144,589 | $299,861 | $288,918 |
| Net Loss | $(1,999,694) | $(1,799,460) | $(6,758,630) | $(6,644,370) |
| Loss Per Share (Basic/Diluted) | $(0.99) | $(1.70) | $(3.83) | $(6.68) |
| Cash and Cash Equivalents | $73,912 | $739,006 (Dec 31, 2023) | $73,912 (Sep 30, 2024) | $1,236,747 (Sep 30, 2023) |
| Working Capital Deficit | $(1,287,315) | N/A | $(1,287,315) | N/A |
| Accumulated Deficit | $(17,985,966) | $(11,228,173) (Dec 31, 2023) | $(17,985,966) | $(8,660,126) (Sep 30, 2023) |
Material Changes vs. Prior Period
- Revenue Decline (Q3): Revenue decreased 45.6% in Q3 2024 compared to Q3 2023, attributed to delays in marketing activities caused by migrating to a new telehealth platform.
- Revenue Growth (YTD): Year-to-date revenue increased 4.8% compared to the prior year, driven by increased digital marketing and recurring subscriptions.
- Operating Expenses: Total operating expenses decreased slightly in Q3 but increased significantly in stock-based compensation ($567,619 in Q3 2024 vs. $151,592 in Q3 2023) due to bonuses and stock issuances for services.
- Intangible Assets: Total assets increased significantly due to the acquisition of patents valued at $14.61 million, paid for primarily through the issuance of Series C Convertible Preferred Stock.
- Liquidity: Cash balances dropped from $739,006 at year-end 2023 to $73,912 at September 30, 2024, primarily due to operating losses and funding the patent acquisition.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With a working capital deficit of approximately $1.3 million and an accumulated deficit of nearly $18 million, management states that current capital resources are insufficient to fund operations for the next 12 months without additional financing.
- Strategic Alternatives: The Board has initiated a formal review of strategic alternatives, which could include business combinations, asset liquidations, or a sale of the Company.
- Legal Contingency: In a subsequent event (October 2024), the Company learned that Eli Lilly has filed a lawsuit alleging the Company improperly copied its weight-loss medicines (Zepbound and Mounjaro). The Company refutes these claims and intends to defend itself vigorously.
- Financing Activities: The Company has secured an Equity Line of Credit (ELOC) and a Securities Purchase Agreement (SPA) for Series B Preferred Stock to raise capital. Proceeds from these instruments are critical for operations but will result in significant shareholder dilution.
- Related Party Transactions: A significant portion of costs of revenue and operating expenses involves related parties, including loans from the CEO and pharmacy services from an entity controlled by the CEO.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $73,912 cash balance against the stated need for additional funding to survive the next 12 months.
- Dilution Impact: Assess the potential dilution from the conversion of Series B and Series C Preferred Stock and the exercise of outstanding warrants (412,333 warrants outstanding).
- Patent Acquisition: Review the terms of the $20 million patent purchase from Intramont Technologies, specifically the cash payment obligations ($375,000 remaining as of Sep 30) and the royalty structure.
- Legal Risk: Monitor the status of the Eli Lilly lawsuit regarding compounded tirzepatide and the potential for injunctions or damages.
- Related Party Dependence: Evaluate the financial impact of reliance on related parties for pharmacy services (Epiq Scripts) and short-term liquidity (loans from Cohen Enterprises/Ronin Equity).
- Nasdaq Compliance: Confirm continued compliance with Nasdaq listing requirements, specifically the minimum bid price, following the recent reverse stock split.